Ceftazidime-avibactam for the Treatment of Multidrug-resistant Pseudomonas aeruginosa Central Nervous System Infection in Pediatric Patient: A Case Report. 2022

Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
From the Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Very limited experimental and clinical data are currently available regarding the cerebrospinal fluid (CSF) penetration of ceftazidime-avibactam in adults. Nevertheless, up to our knowledge, there are no data of ceftazidime-avibactam use in central nervous system infections in pediatric patients. For that, here we describe our experience with the use of ceftazidime-avibactam in addition to intraventricular colistin in a pediatric patient diagnosed with ventriculoperitoneal shunt infection due to multidrug-resistant P. aeruginosa. A 2-year-old boy known to pre-term, delivered at 26 weeks with hydrocephalus that required ventriculoperitoneal shunt which was infected due to P. aeruginosa. He was treated with multiple antipseudomonal agents; however, cultures remained persistently positive. On day 54 of admission, the isolate was reported as multidrug-resistant P. aeruginosa and he was switched to ceftazidime-avibactam and intraventricular colistin. CSF cultures became sterile 3 days after initiation of this antibiotic regimen, and subsequent CSF cultures had no growth. No recurrent episode of central nervous system infections due to P. aeruginosa occurred up to 2 years of follow-up.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D002494 Central Nervous System Infections Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process. CNS Infections,Central Nervous System Infection,Infections, Central Nervous System,CNS Infection,Infection, CNS,Infections, CNS
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003091 Colistin Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. Polymyxin E,Colimycin,Colisticin,Colistin Sulfate,Coly-Mycin,Totazina,Sulfate, Colistin
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
August 2022, Infection,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
January 2023, Infection and drug resistance,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
March 2020, Acta microbiologica et immunologica Hungarica,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
January 2022, Frontiers in medicine,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
February 2020, Pediatric pulmonology,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
July 2019, The Journal of infectious diseases,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
January 2023, Infection and drug resistance,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
December 2018, Journal of global antimicrobial resistance,
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
May 2021, Infectious diseases (London, England),
Thamer A Almangour, and Sarah Alsubaie, and Leen Ghonem, and Hissah A Almohaini, and Hind Mohammed Bakheet, and Ikhlass Altweijri
January 2020, Access microbiology,
Copied contents to your clipboard!